诺思格（301333）：行业需求回暖，业绩稳健向上

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a revenue of 607 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09%. The net profit attributable to the parent company was 96 million yuan, up 13.21% year-on-year. In Q3 alone, revenue reached 228 million yuan, a 24.48% increase year-on-year, with net profit growing by 32.98% to 34 million yuan [4] - The clinical business shows signs of recovery, with an increase in order volume and a stabilization of prices due to the recovery in domestic biopharmaceutical demand. The company is expected to see further improvements in gross margin due to refined management and the application of AI technology [4] - The company has optimized its expense structure, with sales expense ratio at 1.66%, management expense ratio at 10.07%, and R&D expense ratio at 7.54% for the first three quarters of 2025. In Q3, the sales expense ratio was 1.65%, management expense ratio decreased to 8.45%, and R&D expense ratio was 6.63% [5] Financial Projections - The company is projected to achieve revenues of 782 million yuan, 873 million yuan, and 972 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 5.1%, 11.7%, and 11.3%. The net profit attributable to the parent company is expected to be 151 million yuan, 174 million yuan, and 200 million yuan for the same years, with growth rates of 7.5%, 15.6%, and 14.7% respectively [6] - The gross margin is expected to improve from 37.1% in 2024 to 38.8% in 2027, indicating a positive trend in profitability [8]